Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Capital Expenditures: 2016-2025

Historic Capital Expenditures for Tg Therapeutics (TGTX) over the last 7 years, with Sep 2025 value amounting to $80,000.

  • Tg Therapeutics' Capital Expenditures rose 233.33% to $80,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $168,000, marking a year-over-year increase of 342.11%. This contributed to the annual value of $45,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Capital Expenditures is $80,000, which was up 90.48% from $42,000 recorded in Q2 2025.
  • Tg Therapeutics' Capital Expenditures' 5-year high stood at $175,000 during Q2 2021, with a 5-year trough of $3,000 in Q4 2022.
  • In the last 2 years, Tg Therapeutics' Capital Expenditures had a median value of $25,000 in 2025 and averaged $38,400.
  • As far as peak fluctuations go, Tg Therapeutics' Capital Expenditures spiked by 288.89% in 2021, and later slumped by 96.25% in 2022.
  • Quarterly analysis of 4 years shows Tg Therapeutics' Capital Expenditures stood at $80,000 in 2021, then plummeted by 96.25% to $3,000 in 2022, then reached $21,000 in 2024, then spiked by 233.33% to $80,000 in 2025.
  • Its last three reported values are $80,000 in Q3 2025, $42,000 for Q2 2025, and $25,000 during Q1 2025.